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Many viral vaccines, including the majority of influenza vaccines, are grown in embryonated chicken eggs
and purified by sucrose gradient ultracentrifugation. For influenza vaccines this process is well estab-
lished, but the viral strains recommended for use in vaccines are updated frequently. As viral strains
can have different growth properties and responses to purification, these updates risk changes in the
composition of the vaccine product. Changes of this sort are hard to assess, as influenza virions are com-
plex structures containing variable ratios of both viral and host proteins. To address this, we used liquid
chromatography and tandem mass spectrometry (LC-MS/MS), a flexible and sensitive method ideally sui-
ted to identifying and quantifying the proteins present in complex mixtures. By applying LC-MS/MS to
the pilot scale manufacturing process of the live attenuated influenza vaccine (LAIV) FluMist
Quadrivalent vaccine (AstraZeneca), we were able to obtain a detailed description of how viral and host
proteins are removed or retained at each stage of LAIV purification. LC-MS/MS allowed us to quantify the
removal of individual host proteins at each stage of the purification process, confirming that LAIV purifi-
cation efficiently depletes the majority of host proteins and identifying the small subset of host proteins
which are associated with intact virions. LC-MS/MS also identified substantial differences in the retention
of the immunosuppressive viral protein NS1 in purified virions. Finally, LC-MS/MS allowed us to detect
subtle variations in the LAIV production process, both upstream of purification and during downstream
purification stages. This demonstrates the potential utility of LC-MS/MS for optimising the purification of
complex biological mixtures and shows that it is a promising approach for process optimisation in a wide
variety of vaccine manufacturing platforms.
 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Influenza A viruses (IAV) and influenza B viruses (IBV) are
highly transmissible human respiratory pathogens. In most years
they kill 290,000–650,000 people globally, cause widespread mor-
bidity and inflict major economic costs [1,2]. The primary method
for controlling the disease is vaccination and the WHO recom-
mends annual vaccinations for healthcare workers and those
most at risk of severe complications from influenza [3], including
pregnant women [4], young children [5], older adults [6] and
individuals with certain underlying health conditions [7]. A num-
ber of governments also recommend the vaccination of school
children and healthy adults to decrease the impact of seasonal
epidemics [8].
Table 1
Live Attenuated Influenza Vaccine (LAIV) Strains.
Short
Name
Full Name Genus
(Subtype/
Lineage)
Secondary
incubation
A/BOL13 A/Bolivia/559/2013 A (H1N1) 48 h, 33 C
A/CAL09 A/California/07/2009 A (H1N1) 72 h, 33 C
A/TEX12 A/Texas/50/2012 A (H3N2) 48 h, 33 C
B/BRIS08 B/Brisbane/60/2008 B (Victoria) 72 h, 31 C
B/MASS12 B/Massachusetts/2/2012 B (Yamagata) 72 h, 31 C
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ing influenza viruses in embryonated chicken eggs [9]. Typically,
harvested egg material is purified and different viral strains are
blended to produce multivalent vaccines. These protect against
the H3N2 and H1N1 subtypes of IAV, and either one (trivalent)
or two (quadrivalent) lineages of IBV. Inactivated influenza vacci-
nes (IIVs) and live attenuated influenza vaccines (LAIVs) both elicit
a humoral immune response; LAIVs also elicit a mucosal immune
response [10,11] which can lead to greater vaccine effectiveness
in children [12–15]. For decades, egg-grown vaccines against influ-
enza and many other viruses have been purified by sucrose gradi-
ent ultracentrifugation [16,17].
Influenza viruses evolve rapidly, and so the strains recom-
mended for influenza vaccines are frequently updated. The strains
can vary in their growth properties and responses to purification,
which creates an ongoing manufacturing challenge. Some optimi-
sation is possible during the ‘upstream’ part of manufacturing, in
which virus is grown in the allantoic cavity of eggs for a variable
period of secondary incubation and temperature. The ‘downstream’
manufacturing process, in which egg-grown virus is concentrated
and purified, is strictly controlled by the process parameters and
critical quality attributes described in the license, but insights into
the behaviour of a particular strain in a manufacturing process can
be facilitated by performing pilot-scale purifications and identify-
ing issues, such as high pressures, filter blockages, or loss of mate-
rial, that may affect full-scale purification.
Optimising the manufacturing process can be helped by under-
standing the composition of vaccine stocks at each stage of their
purification. This is also an issue of quality control: the final pro-
duct must be shown to contain acceptable levels of antigen (if an
IIV) or infectious virus (if an LAIV) and acceptably low levels of
process-related impurities such as host proteins (e.g. ovalbumin).
Determining the proteins present in influenza vaccines is challeng-
ing because influenza virions (and virus-like particles) are complex
biological structures. Their heterogeneous composition incorpo-
rates viral proteins and a great variety of host proteins, over a wide
range of different abundances [18–20]. Rather than obtaining a
complete description of such a complex mixture, commonly-used
assays focus on a small set of specific proteins [9,20–22]. A single
assay which could reliably detect and quantify all viral proteins
and host-encoded proteins would clearly aid vaccine quality con-
trol [9,22]. It would also aid vaccine manufacturing process devel-
opment if the assay could be performed not only on the highly-
purified final product, but on process intermediates in which viri-
ons are heavily diluted in a complex mixture of other material.
Mass spectrometry (MS) is a highly sensitive and flexible
approach for proteomics. MS approaches can be applied to influ-
enza vaccines, but to date they have been applied only to purified
final products and to the detection and quantification of the major
viral surface antigens [23–25]. We previously used liquid chro-
matography and tandem mass spectrometry (LC-MS/MS) for the
comprehensive proteomic characterisation of purified influenza
virions [18]. As we were able to detect not only the major viral pro-
teins but also very low-level host proteins, we reasoned that this
method could be effective in more complex mixtures such as vac-
cine process intermediates [18,22]. We therefore decided to inves-
tigate whether LC-MS/MS was suitable for the proteomic profiling
of a vaccine purification process. As a proof-of-concept, we consid-
ered several strains prepared for inclusion in the quadrivalent LAIV
(QLAIV) produced by AstraZeneca – an intra-nasal spray marketed
as FluMist Quadrivalent in the United States and Canada and Flu-
enz Tetra in Europe. Here, we show that LC-MS/MS can be an
effective, flexible and highly sensitive tool for monitoring protein
composition during LAIV manufacturing. Because of this, we sug-
gest that LC-MS/MS could be useful in many other viral vaccine
manufacturing processes.2. Materials and methods
2.1. Cells, eggs and viruses
Madin-Darby Canine Kidney (MDCK) cells (ECACC) were pas-
saged in cell culture medium (1  Eagle’s Minimum Essential Med-
ium containing non-essential amino acids (EMEM; Biowest),
supplemented with 1.1 g/L sodium pyruvate (Lonza), 2 mM L-
glutamine (Life Technologies), 10% heat inactivated foetal bovine
serum (FBS, VWR) and 50 mg/mL gentamycin (Life Technologies)).
Specific Pathogen Free embryonated chicken eggs (Charles River
Laboratories) were incubated in a rocking incubator at 37 C and
70% humidity for 11 days prior to inoculation. The LAIV viruses
listed in Table 1 were produced by reverse genetics to make ‘6:2
reassortants,’ with six genome segments from a Master Donor
Virus (MDV, for either IAV or IBV), and the two genome segments
encoding HA and NA from a circulating strain [26].2.2. Fluorescent focus assay (FFA)
Confluent MDCK cells in 96-well tissue culture plates were
washed twice with FFA viral growth medium (FVGM; consisting
of cell culture medium without FBS and with 0.5 mg/mL ampho-
tericin B antimycotic (Life Technologies)) and duplicate wells
infected with a 1:10 serial dilution of virus stock in FVGM. The cells
were incubated at 33 C and 5% CO2 for 20 h, washed with cell cul-
ture medium and fixed with 80% acetone in water for 1 h at 20 C.
Cells were dried at 36 C for 30 min and washed with Phosphate
Buffered Saline (PBS) containing 0.5% Tween (PBST) before label-
ling for 1 h at 36 C with sheep antibody against the relevant HA
(obtained from NIBSC-UK or TGA) in PBS with 1% Bovine Serum
Albumin (BSA). Cells were washed with PBST and incubated with
Alexa Fluor 488 donkey anti-sheep IgG (Life Technologies,
A-11015) in 1% BSA in PBS for 1 h at 36 C, washed again with PBST
and dried at room temperature. Titres were calculated from the
mean number of HA-positive foci in two replicate wells, deter-
mined using a Nikon Eclipse Ti inverted fluorescent microscope.2.3. Production of PHF from chicken eggs
For each virus approximately 1.3  102 FFU of influenza virus in
0.1 mL was inoculated into the allantoic cavities of each of approx-
imately 5500 viable 11 day-old eggs, which were then underwent
secondary incubation at 33 C for IAV strains and 31 C for IBV
strains. After secondary incubation (Table 1), allantoic fluid was
harvested and pooled. Samples for analysis were stabilised with
by mixing 100:1 with 6.9% (w/v) sucrose phosphate in water
(200 mM sucrose, 3.8 mM potassium di-hydro phosphate and
7.2 mM di-potassium hydrogen phosphate, pH 7.2) and stored at
80 C. To consider different secondary incubation times, 9 eggs
per time point were inoculated and harvested under the same con-
ditions as above, after 36, 60, 72 or 84 h of incubation at 33 C.
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The purification process for LAIV, used both commercially and
in pilot scale process development laboratories, is outlined in
Table 2. The work described here was carried out at pilot scale in
a process development laboratory using harvest fluid from approx-
imately 5500 eggs. Two methods were used: method 1 was used
for A/BOL13 and A/CAL09, and method 2 for A/TEX12 and B/
MASS12.2.4.1. Generation of clarified harvest fluid (CHF)
A clarification filter chain was constructed using filters of
decreasing size – 8.0 mm (PP2 filter, Sartorius), 1.2 mm (Milligard
Opticap filter, Millipore) and 0.8 mm/0.45 mm (Sartopore 2 Midicap
filter, Sartorius). This was pre-flushed with 15 L of purified water at
approximately 200 mL/min. Approximately 40 L (method 1) or 25 L
(method 2) of PHF were pumped through the clarification filter
chain at a flow rate of 550 mL/min (method 1) or 275 mL/min
(method 2). CHF was collected on an ice bath and mixed at 25–
35 rpm for 5 min at 2–8 C.2.4.2. Generation of dilute centrifuge Pool (DCP)
A 500 kDa hollow fibre membrane cartridge (GE Healthcare)
was pre-flushed with purified water at a flow rate of 2 L/min
(method 1) or 1 L/min (method 2) for at least 5 min. CHF was
passed through at 3 L/min (method 1) or 1.25 L/min (method 2)
until a 4 – 5-fold reduction in volume was achieved by tangential
flow filtration (TFF). The TFF retentate was purified by continuous
flow sucrose gradient ultracentrifugation using a Hitachi CC40 con-
tinuous flow ultracentrifuge with an 800 mL (method 1; pilot-
scale) or 3200 mL (method 2; equivalent to the production scale)
core. The gradient was sampled between the refractive indices of
1.4183–1.3898 nD using an inline refractometer, generating
approximately 140 mL (method 1) or 800 mL (method 2) of pooled
centrifuge fractions. These were diluted with centrifuge diluent
phosphate buffer (CDPB, 65 mM potassium phosphate dibasic
and 35 mM potassium phosphate monobasic, pH 7.2) to reduce
the sucrose content, creating approximately 1.0 L (method 1) or
2.0 L (method 2) of Diluted Centrifuge Pool (DCP).Table 2
Downstream stages of LAIV production.
Stage Abbreviation Description
Pooled Harvest
Fluid
PHF Allantoic fluid is harvested from
approximately 5500 infected chicken
eggs after secondary incubation. Samples
taken for analysis were stabilised with
sucrose phosphate.
Clarified Harvest
Fluid
CHF Unstabilised PHF bulk material is pumped
through a series of filters of decreasing
pore size to exclude cellular material and
tissue debris, giving CHF.
Diluted
Centrifuge
Pool
DCP CHF is concentrated by tangential flow
filtration with a high-molecular weight
cut-off filter. The retentate is subjected to
ultracentrifugation through a sucrose
gradient. Fractions of the appropriate
density are collected and diluted to
reduce the sucrose concentration, giving
the DCP.
Monovalent Bulk MVB The DCP is filtered to give a sterile stock
of MVB.
Live Attenuated
Influenza
Vaccine
LAIV The diluted combination of MVBs for an
A/H1N1, A/H3N2, B/Victoria and B/
Yamagata strain to give a final QLAIV.2.4.3. Generation of monovalent bulk (MVB)
A sterilising-grade 0.45 mm/0.2 mm filter (Sartopore 2 capsule,
Sartorius) was pre-flushed with approximately 150 mL of purified
water at 45 mL/min then used to filter the DCP at a maximum flow
rate of 50 mL/min (Method 1) or 60 mL/min (Method 2) to gener-
ate the MVB. To remove residual virus from the filter, 90 mL of
CDPB containing 0.69% (w/v) sucrose phosphate (final concentra-
tion) was used to flush the filter at a flow rate of 51 mL/min and
this was combined with the filtered MVB.
In an additional step, not representative of LAIV purification, the
PHF and CHF samples of A/TEX12 were concentrated by overlaying
3.6 mL of the sample virus onto an 0.5 mL 30% sucrose cushion in
CDPB and centrifuging in a Beckman JA-25.50 rotor at 18 K rpm
(27 K g) and 4 C for 18 h. The pellet was resuspended with CDPB
to achieve a final viral titre of at least 109 FFU/mL.
2.5. Mass spectrometry
Samples were lysed at room temperature in 8 M urea and fro-
zen before processing. Processing was carried out as described pre-
viously [18,27], with the incorporation of Filter-Aided Sample
Preparation [28], following a protocol described in detail in [29].
Briefly, lysed samples were clarified and proteins collected by cen-
trifugation through a Vivacon 500 10 kDa molecular-weight cut-
off filter unit (Sartorius). Proteins remaining in the filter unit were
reduced with 10 mM tris(2-carboxyethyl) phosphine (TCEP) for
30 min at RT and then alkylated with 50 mM (final) chloroac-
etamide. The sample was washed with 8 M urea in 100 mM ammo-
nium bicarbonate, equilibrated by washing with 6 M urea in
25 mM ammonium bicarbonate, and digested with Lys-C for
1–3 h at 37 C and then with trypsin overnight at 37 C. Peptides
were collected, pooled and lyophilised prior to analysis. As
described previously [18], prior to analysis the majority of digested
samples were mixed with peptides which had been prepared in the
same fashion from protein mass standards (MS Qual/Quant QC
Mix, Sigma Aldrich).
Samples were analysed by LC-MS/MS using an Ultimate 3000
RSLCnano HPLC system (Dionex) run in direct injection mode and
coupled to a Q Exactive mass spectrometer (Thermo) in ‘Top 100
data-dependent acquisition mode with fragmentation by higher-
energy collisional dissociation (HCD). Charge state + 1 ions were
rejected from selection and fragmentation and dynamic exclusion
with 40 s was enabled.
Mass spectra were analysed using MaxQuant 1.5.8.3 analysis
software [30], following a protocol described in [29]. Briefly, data
files for each sample in a comparison were searched together as
separate experiments, using standard settings and the following
parameters: enzyme: trypsin/P; variable modifications: oxidation
(M) and acetyl (Protein N-ter); and fixed modifications: car-
bamidomethyl (C). Label-free quantitation and the iBAQ algorithm
[31] were enabled. Peptide spectra were matched to a database
containing the predicted proteome of each virus in the comparison,
the protein sequences of the protein mass standards (MS Qual/
Quant QC Mix, Sigma Aldrich), a single repeat of the protein
sequence of ubiquitin, and a custom database in which all
instances of the ubiquitin sequence had been deleted from the Gal-
lus gallus UP000000539 proteome (retrieved from UniProt on
16/05/2017). Viral proteins were matched to the predicted consen-
sus sequence, on the assumption that mutations and post-
translational modifications of any individual residue would be
low-frequency events [27]. Protein group data were further
processed by deleting reverse (decoy) matches, potential host pro-
teins, protein groups identified by site only and (except where sta-
ted) the protein standards.
Raw data, the databases used for the searches and tables con-
taining the processed results can be downloaded from Enlighten
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data.707).
2.6. Electron microscopy
For PHF and CHF samples, 30 mL of material was clarified at
1.6 K rpm at 4 C for 10 min and then layered onto a 30% sucrose
cushion, with the remainder of the centrifuge tube filled with
PBS. For DCP and MVB samples 4 mL of material was added to a
centrifuge tube which was then filled with PBS. Samples were cen-
trifuged in a Beckman SW32Ti rotor at 30 K rpm (111K g) at 4 C for
3.5 h (PHF and CHF) or 3 h (DCP and MVB). After centrifugation,
pellets were resuspended in 500 ml PBS, mixed 1:1 with 4% glu-
taraldehyde in PBS and stored at 80 C before being adsorbed to
carbon coated and plasma etched Pioloform grids and stained
with 2% aqueous uranyl acetate in PBS. Grids were examined using
a Philips CM 100 Compustage (FEI) transmission electron
microscope.Fig. 1. Mass spectrometry can determine protein ratios in LAIV in-process material.
(A) LC-MS/MS with label-free quantitation can consistently determine protein
ratios over a wide dynamic range. 24 infected and 12 mock-infected samples of
unpurified allantoic fluid, as well as 12 samples taken throughout the vaccine
purification process, were mixed with purified protein standards and analysed by
LC-MS/MS. In each sample the protein standards, which were always in a fixed
100:100:10:10:1 ratio, were quantified as a proportion of total protein, and all
possible pairwise ratios between the standards within each sample were calculated
(in each pair [protein 1]  [protein 2]). Grey lines show the expected pairwise ratios
and coloured points and trendlines show the measured pairwise ratios. (B) LC-MS/
MS with label-free quantitation can consistently measure the abundance of viral
proteins in unpurified samples. The viral proteins in the allantoic fluid of eggs
infected with A/TEX12 were quantified with respect to each other. Three indepen-
dent experiments are shown, with triplicate technical repeats (repeat injections of
sample into the instrument) for the first experiment. Samples in the first
experiment were concentrated through a sucrose cushion prior to analysis.3. Results
3.1. Mass spectrometry can be used to determine protein ratios during
LAIV production
To determine the protein composition of LAIV production
stages, we adapted an LC-MS/MS approach that we had previously
used to identify and quantify proteins in purified influenza virions
[18]. We first wished to determine whether LC-MS/MS could con-
sistently determine protein ratios in LAIV in-process material,
which was considerably more complex than the material previ-
ously considered. To do this we mixed a set of LAIV samples with
protein standards. These were in a fixed ratio of abundance relative
to each other (1:10:10:100:100) but varied considerably in their
total abundance with a sample, allowing us to assess the repro-
ducibility of protein quantitation over a wide dynamic range.
We could consistently and accurately measure 1:1 ratios of pro-
tein standards, provided they were within the top three orders of
magnitude of total protein abundance (Fig. 1A). As expected, the
amount of noise increased both with greater pairwise ratios and
when the protein standards were increasingly diluted. Despite this,
almost all measured ratios were still within ten-fold of their actual
values even over a dynamic range of 100 for pairwise ratios and at
a proportional abundance of less than 105 in the sample. As in a
previous study [18], we noted stochastic failures to detect very
low abundance proteins, with the least abundant protein standards
being worst affected (data not shown). We concluded that LC-MS/
MS could consistently and accurately determine protein ratios in
LAIV process intermediate samples, although caution was required
when interpreting large pairwise ratios and failures to detect very
low-abundance proteins.
3.2. Mass spectrometry can consistently quantify viral proteins in
process intermediates
We next wished to determine whether the ratios of viral pro-
teins could be reproducibly determined in process intermediates.
To do this, we considered upstream LAIV material consisting of
unpurified allantoic fluid from infected eggs (PHF). This is the man-
ufacturing stage in which viral proteins are most dilute and con-
taminating host proteins most abundant.
In initial experiments, we analysed the PHF from eggs infected
with a former influenza vaccine strain, A/TEX12 (Fig. 1B). We first
quantified viral proteins in a sample concentrated through a
sucrose cushion, making three replicate measurements of the same
material. As we could reproducibly detect and measure the ratiosof the viral proteins, we then compared this to two independent
experimental repeats on which no concentration had been per-
formed. We consistently measured the ratios of viral proteins over
a wide dynamic range, albeit with greater noise at larger ratios
(Fig. 1B).
In further pilot experiments we encountered stochastic failures
to detect the least abundant viral proteins (data not shown). We
noted that a failure to detect the viral polymerase subunits PA,
PB1 and PB2, which are among the least abundant viral proteins
in the virion [18], correlated with a failure to detect other low-
abundance virion proteins such as M2 and NEP. For this reason,
we adopted the detection of at least two polymerase subunits as
872 A. Hawksworth et al. / Vaccine 38 (2020) 868–877an acceptance criterion for analysis. With this condition, we con-
cluded that LC-MS/MS could reproducibly determine the abun-
dance of viral proteins, even in unpurified allantoic fluid.
3.3. Assessment of upstream LAIV material by LC-MS/MS
We next extended our analyses to a panel of influenza A and B
virus LAIV strains (Table 1). The ratios of viral proteins in the PHF
were broadly consistent across strains, allowing for increased noise
and occasional losses of detection when considering the least
abundant proteins (Fig. 2A). This consistency was expected, both
because of the viruses’ common genetic background and becauseFig. 2. Viral protein abundance in upstream LAIV material. Proteins in pooled
harvest fluid (PHF), the starting material for live-attenuated influenza vaccine
(LAIV) production, were assayed by LC-MS/MS with label-free quantitation and by
focus-forming assay. Eggs were infected with different viruses and incubated under
different conditions before harvest, as indicated. (A) Protein abundance in PHF,
normalised by the total abundance of viral proteins in the sample (dashed line). (B)
The ratio of viral protein to total protein in each sample, compared to the infectious
titre. The same symbols are used to indicate each strain in both (A) and (B). (C) The
ratio of viral protein to total protein, and the infectious titre, for PHF harvested from
eggs infected with A/TEX12 and incubated at 33 C for the indicated secondary
incubation times prior to harvest.of a propensity we have previously observed for egg-adapted
viruses to assemble virions with a common ‘core architecture’ [18].
However, there were two striking differences between the PHF
stocks. Firstly, we noted variations in the amount of viral NS1, with
higher levels detected in IAV strains than in IBV strains (Fig. 2A).
Secondly, the total proportion of viral protein in the samples var-
ied, both between strains and between experiments (Fig. 2B). To
examine more closely the ability of LC-MS/MS to detect differences
in viral yield within PHF, we varied the yield of A/TEX12 by altering
the secondary incubation time. The variation in total viral protein
detected using LC-MS/MS correlated with infectivity, indicating
that LC-MS/MS can detect variations in viral protein yield in PHF
(Fig. 2C). Thus, LC-MS/MS can be used to assess the proteomic
composition of upstream LAIV production material. Even in these
complex samples, it can identify changes in both the relative abun-
dance of individual proteins and in the overall viral yield.
3.4. Assessment of purified LAIV material by LC-MS/MS
We next analysed virions in purified (MVB) stocks (Fig. 3A;
Table 3). As expected from purer material, we were able to deter-
mine viral protein ratios more consistently in samples of MVB than
of PHF (Fig. 2A, 3A). Variations in relative host protein abundance
were largely eliminated after virion purification (Fig. 3B) which,
along with the correlation of viral protein with infectious titre in
the PHF (Fig. 2B), indicated that the differences in the host protein
abundance likely arose from differences in the total concentration
of virions in the PHF rather than in differences in composition of
the virions themselves. Although purification to MVB gave greater
consistency in the concentration of viral protein it did not lead to a
consistent infectious titre, indicating that the specific infectivity of
virions after purification was variable (Fig. 3B).
Most viral proteins maintained a consistent ratio during purifi-
cation from PHF to MVB, while the amount of host protein present
was dramatically reduced (Fig. 3C). For the IAV strains, purification
did not change the relative abundance of NS1 (Fig. 3C), supporting
the hypothesis that NS1 is a component of influenza virions [18].
However, this was not the case for the IBV strain B/MASS12. Here,
NS1 was already less abundant in the PHF than it was for the IAV
strains, and it was depleted nearly 80-fold by purification
(Fig. 3C). This suggests that for B/MASS12 NS1 is not a component
of the virion.
Together, these data show that LC-MS/MS can be used to assess
the proteomic composition of purified LAIV stocks and can quantify
viral and host proteins, including those of low abundance, in a sin-
gle measurement.
3.5. Assessment of the downstream LAIV purification processes
by LC-MS/MS
Having established that LC-MS/MS could be applied to both
purified and unpurified material, we used it to examine the effects
of the multi-stage LAIV downstream purification process (Table 2,
see also Materials and Methods). We began by obtaining an overall
impression of the stringency of LAIV purification. Using A/TEX12,
we compared the effects of LAIV purification to one-step concen-
tration through a cushion, an approach commonly used in experi-
mental procedures that require concentrated influenza virions but
do not require a particularly high degree of purity [29]. LC-MS/MS
showed that while a simple concentration step increased the pro-
portion of viral protein in the stock by 8-fold, LAIV purification
removed a greater proportion of host proteins, increasing the pro-
portion of viral protein by 12-fold (Fig. 4A). Importantly for an
LAIV, this process left the virions intact (Fig. 4B).
We next considered each stage in the purification process
(Table 2), using four LAIV strains (Fig. 5A). Filtration between
Fig. 3. Viral protein abundance in purified LAIV material. Proteins in monovalent
bulk (MVB), the purified material resulting from LAIV production, were assayed by
LC-MS/MS with label-free quantitation and by focus-forming assay. Prior to
purification, eggs were infected with different viruses and incubated under
different conditions before harvest, as indicated. (A) Protein abundance in MVB,
normalised by the total abundance of viral proteins in the sample (dashed line). (B)
The ratio of viral protein to total protein in each sample, compared to the infectious
titre. The same symbols are used to indicate each strain in both (A) and (B). (C) A
comparison of the abundance of proteins in unpurified (PHF) and purified (MVB)
material, normalised to total viral protein and with each viral strain plotted as
separate points. Proteins with the same ratio to total viral protein both before and
after purification would lie on the dashed line. For the viral NS1 protein,
annotations indicate the strain to which each point corresponds.
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had a variable effect on viral titre. TFF and gradient ultracentrifuga-
tion between CHF and DCP caused most of the reduction in host
protein concentration and substantially reduced viral titre. Finally,
sterile filtration between DCP and MVB caused a slight but consis-
tent reduction in host material without substantial reductions in
viral titre, suggesting that even after gradient ultracentrifugation
some filterable host material remained. Overall, the purification
process greatly reduced the concentration of host proteins in all
cases.
Most viral proteins maintained a consistent ratio at each stage
of the purification process (Fig. 5B), with the exception of the
NS1 protein of B/MASS12 (Fig. 5C). For B/MASS12, the largest
decrease in NS1 concentration was during the initial filtration step
(PHF to CHF), even though this left the bulk concentration of host
proteins largely unaffected (Fig. 5A, C). This suggests that the
NS1 of B/MASS12 was associated mainly with large particulate
material, such as cellular debris.
As described in the Materials and Methods, our data were col-
lected using four different virus strains and two differently
scaled-down LAIV purification methods. We were able to detect
differences in the efficiency of host protein depletion under these
different conditions (Fig. 5A). Our experimental design was not
intended to systematically compare the effects of these conditions,
but the fact that differences were detectable highlights the utility
of LC-MS/MS for comparing methods during downstream process
optimisation. Overall, these data indicate that LC-MS/MS is suitable
for assessing the efficiency of LAIV downstream purification stages.
3.6. LAIV purification efficiently depletes most egg proteins
Finally, we used our data to produce a detailed description of
how LAIV purification depletes specific host proteins.We compared
the abundance of host proteins in PHF and MVB of the LAIV strains
A/BOL13, A/CAL09, A/TEX12 and B/MASS12, excluding A/TEX12
samples that had undergone additional concentration through a
sucrose cushion. To express protein abundance in terms of maxi-
mum copy number per virion we assumed that each virion incorpo-
rated no more than eight copies of the viral polymerase [18,32].
LAIV purification efficiently removed the majority of host pro-
teins (Fig. 6A). This included ovalbumin (mean depletion 640-
fold), ovotransferrin (1360-fold) and ovomucoid (730-fold), as well
as haemoglobin beta (465-fold) and apolipoprotein A1 (1880-fold),
plausible host proteins from the blood and yolk content of the egg,
respectively. Purification depleted 82% of host proteins by more
than 10-fold, and most of the remainder were present only at very
low abundance (Fig. 6A). When considering purified (MVB) sam-
ples, only a small number of host proteins were present at a greater
abundance than the viral polymerase (Fig. 6B). Among these ubiq-
uitin, the membrane proteins uroplakin-1b and 3a [33] and
mucin-16 have all previously been identified as components of
the influenza virion [18]. Actin, tubulins, lysozyme C, ovalbumin
and BPI fold-containing family B member 2, though present, were
all depleted by tens to hundreds of fold during the purification pro-
cess. In this way, LC-MS/MS provided a protein-level description of
the depletion of host proteins during LAIV purification and of the
proteomic composition of material prepared in a comparable
way to the final LAIV product.4. Discussion
LAIVs such as the FluMist vaccine require the purification of a
range of influenza strains using a single manufacturing process.
Table 3
Maximum viral proteins per virion.
Protein A/BOL13 A/CAL09 A/TEX12 B/MASS12 Mean ± s.d.
M1 1064 529 1320 342 814 ± 456
NP 455 471 568 386 470 ± 75
HA 178 384 386 522 367 ± 142
NA 160 146 508 179 249 ± 174
M2 22 21 32 13 22 ± 8
NEP 3 6 3 8 5 ± 3
NS1 322 90 194 0 152 ± 139
NB 0 0 0 1 N/A
PB2 9 10 10 9 9 ± 1
PB1 9 7 7 8 8 ± 1
PA 6 7 7 8 7 ± 0
NB: Data from MVB stocks, scaled to assume no more than eight polymerase subunits per virion.
Fig. 4. The effects of purification on influenza virions. (A) The abundance of viral
proteins in the allantoic fluid of eggs infected with A/TEX12 determined by LC-MS/
MS, as in Fig. 1B, comparing allantoic fluid when unpurified, concentrated through a
30% sucrose cushion by ultracentrifugation, and purified using sucrose density
gradient ultracentrifugation as for vaccine production. For unpurified and gradient-
purified samples the mean and range of two independent experiments are shown;
for the cushion the mean and SEM of three replicate measurements. (B) Negative-
stain transmission electron microscopy (TEM) showing virions of A/TEX12 at each
of the stages of vaccine purification: pooled harvest fluid (PHF), clarified harvest
fluid (CHF), dilute centrifuge pool (DCP) and monovalent bulk (MVB). Scale bars are
500 nm. PHF and MVB correspond to the ‘unpurified’ and ‘gradient’ steps in (A),
respectively.
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ing high levels of purity along with an acceptable viral yield can be
a major challenge. This makes a simple method to produce detailed
measurements of compositional changes during LAIV purification
highly desirable. Firstly, such a method would offer the possibility
of optimising the current manufacturing process, and secondly it
could facilitate the development of a more efficient subtype- or
strain-specific downstream purification process in the future. The
current sucrose-gradient ultracentrifugation process is extremely
costly, time- consuming and requires a high level of expertise toexecute. There may be significant benefits in developing an alter-
native downstream purification process using diafiltration or chro-
matography [34], but any new processes would need to be
thoroughly characterised to allow process development and to
demonstrate that an optimised process produces a product suit-
able for market. Here, we show that LC-MS/MS is a suitable tool
for the sensitive and detailed characterisation of LAIV-in process
material in a single measurement. We therefore suggest that it
could be of use in the optimisation and development of vaccine
purification processes.
LC-MS/MS was sensitive enough to be applied to upstream (pre-
purification) material, where it could detect differences in both
total yield and in the initial purity of virions of the sort that
routinely arise when preparing vaccines from eggs (Fig. 2).
Batch-to-batch variation of eggs is an acknowledged issue in influ-
enza vaccine production, with anecdotal evidence suggesting that
differences in farm, flock lineage and flock age can all affect viral
yields [35]. LC-MS/MS offers an attractive process development
tool with the potential to help understand and therefore reduce
this variability, as well as helping to optimise the secondary incu-
bation time and temperature for new strains.
LC-MS/MS was also used to profile downstream purification
stages. We demonstrated proof-of-concept for the use of LC-MS/
MS in downstream process optimisation by comparing the purifi-
cation of four different viral strains under two different methods,
and by identifying an unanticipated increase in virion purity dur-
ing final sterile filtration. It should be noted that strain-specific
process changes do not always have identical effects at pilot scale
and commercial scale. Scale-driven differences in critical quality
attributes, such as product titre and the clearance of impurities,
can require remedial process changes. As the composition and
complexity of pilot scale material resembles that of material pro-
duced at commercial scale, we would expect that LC-MS/MS would
also be suitable for the assessment of commercial scale material.
The production of highly purified LAIV requires the removal of
host proteins such as ovalbumin, which as well as being an aller-
gen can reduce viral titre [36]. Considerable work has already been
done to optimise LAIV process development, and it is important to
note that current commercial purification methods reduce the con-
centration of ovalbumin to a point where LAIV can be safely
administered to people with egg allergies [37–39]. Indeed, a recent
study found that commercially available LAIV had the lowest levels
of ovalbumin of any influenza vaccine available on the market [40].
The proteomic profiles produced by LC-MS/MS extend our ability
to assess the purity of the final product. By characterising MVB
stocks, comparable to those used in formulating a commercial LAIV
product, we have provided what is, to our knowledge, the most
detailed published proteomic assessment of a vaccine prepared
by sucrose-gradient ultracentrifugation. By their very nature, the
virions of an enveloped virus such as influenza contain some host
Fig. 5. Viral protein abundance during LAIV purification. Influenza vaccine strains were purified from allantoic fluid as for LAIV production; the strain A/TEX12 underwent
additional concentration through a 30% sucrose cushion prior to analysis. (A) The effects of purification on viral and host protein abundance (determined by label-free LC-MS/
MS) and infectious titre for four different LAIV strains. For A/TEX12 the mean and SEM of 3 (PHF) or 2 replicate measurements are shown. (B) The abundance of viral proteins
at each stage of purification, compared to their average abundance across all stages, showing the means and standard deviations from A/BOL13, A/CAL09 and B/MASS12.
(C) The abundance of NS1, compared to its average across all stages, showing the mean and range of A/BOL13 and A/CAL09 as NS1 (A) and B/MASS12 as NS1 (B).
A. Hawksworth et al. / Vaccine 38 (2020) 868–877 875proteins (Fig. 6) [18,19]. Although these host proteins do not pose a
risk in a vaccine [37–39], it is clearly desirable that we know what
they are, and a comprehensive proteomic description by LC-MS/MS
allows for this.
Our data confirm the expectation that LAIV strains, possessing
the same MDV ‘backbone,’ produce virions with the same broadly
conserved ‘core architecture’ of proteins. However, we noted that
the incorporation of the viral protein NS1 into virions varied mark-
edly (Figs. 2, 3). We previously detected NS1 in purified IAV and
IBV virions at levels close to that of the viral polymerase [18]. In
contrast, in this study, NS1 associated with IAV virions at higher
levels, closer to that of the viral NA (Fig. 3), while for B/MASS12
NS1 appeared to be separable from virions by filtration(Figs. 3, 5C). Together, these data suggest that, unlike the broadly
consistent incorporation of the other viral proteins, influenza viri-
ons incorporate variable amounts of NS1. NS1 is a multi-functional
and potently immunosuppressive protein [41] but the functions of
extracellular NS1 are unknown. However, we note that LAIV
strains, including those used in this study, are extensively tested
in release assays. We therefore know that the reduced association
of NS1 with B/MASS12 does not significantly affect the strain’s
capacity to generate an immune response and provide protection
from circulating strains [14].
In summary, LC-MS/MS provides a suitable platform for opti-
mising viral vaccine purification processes. Applied at the pilot
scale, as here, it can be used when optimising current methods
Fig. 6. Host protein abundance during LAIV purification. Comparison of protein abundance before (PHF) and after (MVB) purification, normalised by assuming a maximum 8
polymerase subunits per virion. (A) Average PHF and MVB protein abundance in the strains A/BOL13, A/CAL09, A/TEX12 and B/MASS12 (excluding A/TEX12 PHF samples that
had been purified through a cushion), showing means and standard deviations. Dashed lines show the degree of depletion after purification. (B) Host proteins whose mean
abundance across strains, after purification, is greater than that of the viral polymerase. Abundance in the MVB and the degree of depletion during purification is shown for
each of the viral strains. UPK1B: uroplakin-1b; UPK3A: uroplakin-3a; UBB: ubiquitin; Muc16: mucin-16; TUBA1C: tubulin alpha chain; TUBB: tubulin beta chain; ACTB: actin;
BPIFB2: BPI fold-containing family B member 2; LYSC: lysozyme C; OVAL: ovalbumin.
876 A. Hawksworth et al. / Vaccine 38 (2020) 868–877for the purification of LAIV and of many other viral vaccines. It can
also be used for assessing the scalability of these methods to com-
mercial processes, which is currently a significant challenge in bio-
logics [42–44]. LC-MS/MS therefore provides a powerful and
flexible tool for vaccine optimisation and development.Declaration of Competing Interest
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